Accellix
Cell Therapy Quality Control
Company Overview
Snapshot
Founded in March 2009 by Harvey Kasdan, Accellix operates with 51–200 employees. The company has raised $18.73M across 7 funding rounds from 3 investors. In June 2020, Accellix raised a Series D round.
Business overview
Accellix develops a platform for quick and accurate flow cytometry results, designed for use in manufacturing and at the point of care. The company's core technology enables partners in cell therapy to meet critical quality control requirements, advancing life-changing therapies. Accellix operates within the Health Tech & Life Sciences sector, specifically focusing on medical devices and diagnostics for laboratories and healthcare providers.
Strategic signal
In May 2021, Accellix expanded its leadership team, signaling a strategic move to strengthen its executive capabilities and potentially accelerate growth or market penetration in the cell therapy quality control space. This expansion suggests a focus on scaling operations or pursuing new strategic initiatives, which is a positive indicator for investors looking for companies with robust management structures to support future development.
Company Intelligence Q&A
- What is Accellix's core mission?
- Accellix's mission is to provide quick and accurate flow cytometry results through a compact and easy-to-use platform, intended for use on the manufacturing floor and at the point of care.
- When did Accellix last expand its leadership team?
- Accellix expanded its leadership team in May 2021, as reported by Business Wire.
- Did Accellix announce any co-development agreements?
- Yes, in October 2019, Orgenesis announced a co-development agreement with Accellix.
- When did Accellix raise its Series D funding round?
- Accellix raised its Series D funding round in June 2020, with participation from bioMérieux.
- What significant product development did Accellix announce in 2020?
- In April 2020, Accellix announced its next-generation instrument and consumable designed to further simplify and automate the QC workflow in cell therapy manufacturing.